Let's Combinate - Pharma + Medical Devices with Subhi Saadeh
Subhi Saadeh
Latest episode
271 episodes
263 - Legendary Former FDA Investigator Challenges How Pharma Approaches GMP Risk, ALCOA & Data Integrity
16/11/2026 | 27 mins.Former FDA Investigator Explains Why Your Risk Assessment Is All Green | Peter Baker
When management treats a red risk as a compliance failure, how honestly can a team assess its processes?
Former FDA investigator Peter Baker returns to Let’s Combinate: Drugs + Devices for a conversation with Subhi Saadeh about data integrity, quality risk management, and the problems hidden inside an all-green risk assessment.
Peter challenges the familiar justification that “we’ve never had a deviation” means something is unlikely to happen. He explains his approach to evaluating vulnerability in processes involving people, asking whether a failure can happen, whether it would be detected, and whether it can be prevented.
We also discuss ALCOA+, the patient impact of incomplete or inaccurate data, differences between pharmaceutical and medical device risk management, and how data governance connects process design, operation, and monitoring.
CHAPTERS
00:00 Peter Baker returns
01:06 How FDA inspections led him to data integrity
01:54 Trial injections and pretesting samples
03:18 ALCOA+ and the impact on patients
05:13 Part 11, Annex 11, and FDA’s regulatory approach
08:35 Why data integrity problems persist
11:44 Where are the red risks?
12:49 Human behavior and the limits of probability
13:41 Assessing vulnerability
14:46 ICH Q9 and ISO 14971
16:43 FMEA, detectability, and probability of harm
18:34 Can it happen, be detected, or be prevented?
20:12 Lessons from combination products
21:51 Connecting deviations and complaints to the risk file
23:24 Why companies need data governance
25:03 Design, operation, and monitoring
26:10 Resources for learning more
27:36 Connect with Peter Baker
ABOUT PETER BAKER
Peter is the Founder and President of Live Oak Quality Assurance, specializing in data integrity, data governance, and quality risk management. He spent 11 years with the FDA, including seven years in its overseas offices in India, China, and Chile. Named FDA Investigator of the Year in 2013, he conducted more than 100 foreign drug inspections. His investigative work is featured in Katherine Eban’s bestselling book Bottle of Lies.
ABOUT SUBHI SAADEH
Subhi is the Founder and Principal of Combinate, a consulting practice specializing in combination product quality, drug delivery systems, and the intersection of pharmaceutical and medical device requirements. His background includes engineering, manufacturing, and quality leadership experience at Baxter, Pfizer, and Gilead Sciences. He hosts Let’s Combinate: Drugs + Devices, exploring the people, processes, and decisions behind product quality.
Learn more about Peter’s work at [Live Oak Quality Assurance](https://www.liveoakqa.com).- Pharma outsourcing, CDMO selection, and contract manufacturing are changing as biotech funding, manufacturing capacity, and sponsor expectations shift. Raman Sehgal joins Subhi Saadeh to discuss the CDMO market in 2026, what makes a reliable manufacturing partner, and how AI in drug discovery could shape demand for outsourced development and manufacturing.
Recorded at CDMO Live Americas, this conversation examines what happens when a supplier’s capabilities look right on paper, but the experience of working with them falls short. Raman shares his perspective on how the industry grew, why some biotech clients feel overlooked by large CDMOs, and where smaller providers have an opportunity to compete.
We discuss:
• How pharma outsourcing evolved from transactional manufacturing to strategic partnerships
• What site visits, employee enthusiasm, and company culture reveal about a supplier
• Why customer experience matters from the first RFP through batch delivery
• How biotech funding and post-COVID changes affected CDMO demand
• Differences in capacity across oral solid dose and sterile fill-finish manufacturing
• Risk-sharing, pricing models, and aligned incentives between sponsors and CDMOs
• How GLP-1s and peptides created opportunities for some manufacturers
• AI-driven drug discovery, preclinical research, and the lag before new molecules reach manufacturing
• Why Raman recommends starting AI adoption with business processes
ABOUT RAMAN SEHGAL
Raman Sehgal is the founder of ramarketing and host of the Molecule to Market podcast. He also co-founded Lead Candidate, a talent acquisition business serving the pharmaceutical outsourcing sector. He brings more than two decades of experience working with CDMOs and pharmaceutical service providers.
ABOUT SUBHI SAADEH
Subhi Saadeh is a combination product quality consultant, founder of Combinate, and host of Let’s Combinate. His experience spans pharmaceutical and medical device quality, supplier and contract manufacturer oversight, audits, and quality systems. He helps pharma companies solve device problems and device companies solve pharma problems.
Find Raman on LinkedIn and listen to Molecule to Market. Subscribe to Let’s Combinate for conversations on combination products, drug delivery, pharmaceutical manufacturing, and quality.
Thank you to the CDMO Live Americas team for making this conversation possible. 261 - Getting Pharma/Device Products Into Clinical Trials: INDs, IDEs & FDA Meetings
02/11/2026 | 37 mins.Getting pharma, medical device, and drug-device combination products into clinical trials takes a clear strategy for INDs, IDEs, FDA meetings, and first-in-human studies.
Dr. Robert Bilkovski joins Subhi Saadeh to discuss clinical development, pre-IND meetings, Q-Submissions, clinical trial design, site selection, and sponsor oversight.
What should you have figured out before meeting with FDA? How does the clinical strategy change when you pair an existing drug with a new delivery device? And what happens between preparing a submission and enrolling the first patient?
IN THIS EPISODE
The chief medical officer’s role in clinical development, safety, and medical affairs• Clinical strategy for drugs, medical devices, and combination products• Bridging an existing drug to a new delivery device• INDs, IDEs, and preparing for first-in-human studies• Bringing focused questions and a proposed strategy to FDA meetings• Using early studies to inform endpoints, sample sizes, and labeling• Selecting, qualifying, and activating clinical trial sites• Sponsor oversight and considerations for studies outside the United States
ABOUT DR. ROBERT BILKOVSKI
Contact Robert: http://www.RNBVenturesConsulting.com/podcast
Dr. Robert Bilkovski is an emergency physician whose industry experience includes Hospira, GE Healthcare, and Abbott Molecular. He advises companies on clinical development as a fractional chief medical officer and is the author of Make Your Story Believable: Diagnosing the Pitfalls of Healthcare Innovation.
ABOUT SUBHI SAADEH
Subhi Saadeh is the founder of Combinate and host of Let’s Combinate, helping pharmaceutical and medical device companies solve the quality challenges where drugs and devices meet. His career spans engineering and quality roles at Baxter, Pfizer, and Gilead, supporting drug delivery systems and combination products from development and clinical use through launch and commercial manufacturing.
His experience includes prefilled syringes, autoinjectors, infusion devices, and a frozen prefilled syringe platform supplying more than 100 million units annually. He has chaired industry working groups through the Combination Products Coalition and Rx-360, contributed to AAMI’s combination product work, and co-created the CQA Master Class. Subhi is an ASQ Certified Quality Auditor and Certified Quality Engineer, an ISO 13485 Lead Auditor, and a bioengineering graduate of the University of Illinois Chicago.
WORK WITH SUBHI
Consulting, audits, and training:https://letscombinate.com/services/
Discuss your project:https://calendly.com/letscombinate/quick-chat
LinkedIn:https://www.linkedin.com/in/subhi-saadeh-1169aa21/
Email: subhi@letscombinate.com
RESOURCES
Free guide: Drug vs. Device Qualityhttps://letscombinate.kit.com/216fbfc6c2
CQA Master Class:https://cqeacademy.teachable.com/p/the-cqa-master-class-course
FOLLOW LET’S COMBINATE
YouTube:https://www.youtube.com/@LetsCombinate
Spotify:https://open.spotify.com/show/71wYadhCrfLsdYTVachpD2
Apple Podcasts:https://podcasts.apple.com/us/podcast/lets-combinate-drugs-devices/id1589285792
#ClinicalTrials #CombinationProducts #FDA- What pharma companies want from CDMOs, and how closely that matches what CDMOs think matters. Recorded at CDMO Live Americas with Kaan Kekec, Partner at Simon-Kucher, on the CDMO Growth Report 2026: why quality ranked first for sponsors while CDMOs emphasized speed, how to validate a value proposition, and pricing challenges for drug delivery devices.
Drawing on research conducted with PharmaSource, Kaan explains the gap between sponsor expectations and supplier perceptions. We discuss why quality needs to be demonstrated throughout a partnership, how companies can validate their value proposition, and what drug delivery device suppliers miss when they don't understand the markets their products ultimately serve.
IN THIS EPISODE
- Why quality ranked first for sponsors while CDMOs placed more weight on speed
- Why your value proposition needs to reflect what customers recognize and value
- How customer interviews and competitor comparisons reveal blind spots
- Why large pharma and small biotech need different conversations
- How access to technical experts can influence customer experience and win rates
- Pricing challenges for drug delivery devices across regions and end markets
- Integrated device manufacturing, fill-finish, and assembly
- Why certifications alone don't tell the whole quality story
- How clearer expectations can improve sponsor-CDMO partnerships
ABOUT KAAN KEKEC
Kaan-Fabian Kekec is a Partner at Simon-Kucher with 15 years of consulting experience helping pharma services and drug delivery companies improve their commercial strategy, pricing, and customer value proposition.
Kaan on LinkedIn:
https://www.linkedin.com/in/kaan-fabian-kekec-3b799632/
CDMO Growth Report 2026 (Simon-Kucher, with PharmaSource):
https://www.simon-kucher.com/en/insights/cdmo-growth-report-2026
Thank you to Luke and the CDMO Live team for the opportunity to record this conversation in person.
https://pharmasource.global/events/cdmo-live-americas/
RELATED VIDEOS
Working with a Device CDMO: Common Sponsor Mistakes
https://youtu.be/d2SDwndXuCk
What Is a Quality Agreement? Pharma, Medical Device, and CDMO Responsibilities
https://youtu.be/ocohmInoHkE
Co-Packaged Combination Product Kits: How to Qualify a Finished Device and Its Supplier
https://youtu.be/BEoEr4ljEo4
Need help with CDMO oversight, quality agreements, or supplier audits on a combination product?
https://letscombinate.com/services/
Free guide: Drug vs. Device Quality comparison
https://letscombinate.kit.com/216fbfc6c2
ABOUT SUBHI SAADEH
Subhi Saadeh is the Founder and Principal of Let's Combinate, a consultant, auditor, and trainer specializing in drug-device combination products, medical devices, and pharmaceutical quality systems. He has held quality and engineering roles at Pfizer, Gilead, and Baxter, with a focus on design controls, supplier quality, inspection readiness, and translating regulatory expectations into practical execution.
Subhi is an ISO 13485 Lead Auditor and an ASQ Certified Quality Auditor and Certified Quality Engineer. He has chaired the Combination Product Working Group for Rx-360, served as International Committee Chair for the Combination Products Coalition (CPC) and as a member of ASTM Committee E55, and served on AAMI's Combination Products Committee.
CONNECT WITH SUBHI
Consulting, audits, and training:
https://letscombinate.com/services/
Discuss a project:
https://calendly.com/letscombinate/quick-chat
LinkedIn:
https://www.linkedin.com/in/subhi-saadeh-1169aa21/
Email:
subhi@letscombinate.com
FOLLOW LET'S COMBINATE
YouTube:
https://www.youtube.com/@LetsCombinate
Spotify:
https://open.spotify.com/show/71wYadhCrfLsdYTVachpD2
Apple Podcasts:
https://podcasts.apple.com/us/podcast/lets-combinate-drugs-devices/id1589285792
#CDMO #PharmaOutsourcing #CombinationProducts - Career growth in pharma and medical devices takes technical knowledge, leadership, and the ability to earn your team’s trust. In this episode, Subhi Saadeh shares a lesson from leading a drug-device combination product program that changed how he approached his career in quality.
Early in my career, I was excited about getting on big projects, gaining exposure, and proving what I could do. But leading a team with deeper technical expertise than I had taught me something I had to learn the hard way: it’s not about you.
I share how asking questions, following through, and helping people address their problems helped me earn their respect and become a more effective lead.
In this episode:
- Understanding what your team and stakeholders need from you
- Leading technical experts while building your own experience
- Being coachable and following through on what you learn
- Applying customer focus beyond the quality system
- Building credibility by helping others move their work forward
- What a mentor meant by “their cookie, your crumb”
Chapters:
00:00 The career lesson: It’s not about you
00:25 Career exposure and proving yourself
00:53 Why people value having you around
01:17 Customer focus in quality and leadership
02:03 Leading a complex combination product program
03:25 Feeling out of your depth
03:42 Understanding what your team needs
04:02 Being coachable and earning credibility
05:07 Rethinking career growth and success
06:10 “Their cookie, your crumb”
About Subhi:
Subhi Saadeh is a Quality Professional, Founder & Principal of Combinate, and host of Let’s Combinate: Drugs + Devices. With a background in Quality, Manufacturing Operations, and R&D, he has works with medical device and pharmaceutical organizations supporting the development and launch of combination products for vaccines, generics, and biologics.
Subhi served as the International Committee Chair for the Combination Products Coalition (CPC) and was a member of ASTM Committee E55. He previously served on AAMI’s Combination Products Committee. He is an ASQ Certified Quality Auditor (CQA), Certified Quality Engineer (CQE), and ISO 13485 Lead Auditor.
Connect and learn more:
Website: [letscombinate.com](https://letscombinate.com)
LinkedIn: [Subhi Saadeh](https://www.linkedin.com/in/subhi-saadeh-1169aa21/)
Email: subhi@letscombinate.com
CQA Master Class: [Become a Certified Quality Auditor](https://cqeacademy.teachable.com/p/the-cqa-master-class-course)
Watch and listen:
[YouTube](https://www.youtube.com/@LetsCombinate)
[Spotify](https://open.spotify.com/show/71wYadhCrfLsdYTVachpD2)
[Apple Podcasts](https://podcasts.apple.com/us/podcast/lets-combinate-drugs-devices/id1589285792)
Subscribe for weekly conversations where drugs and devices meet.
For questions, inquiries, or suggestions, please reach out at letscombinate.com or email subhi@letscombinate.com.
More Life Sciences podcasts
Trending Life Sciences podcasts
About Let's Combinate - Pharma + Medical Devices with Subhi Saadeh
Hello Combi-Nation!
Our industry fee complicated sometimes. Drugs, devices, clinical trials, submissions, sterilization validation, design control, risk management, market access reimbursement, the list goes on.
My name is Subhi Saadeh. I've spent over a decade in medical device, pharma, and combination product development. My goal is mastery, so this podcast is to ask questions I have to people who may have the answers.
Whether you're background is Pharma, Device or both, I invite you to listen and together we can simplify by Combinating!
Podcast websiteListen to Let's Combinate - Pharma + Medical Devices with Subhi Saadeh, Short Wave and many other podcasts from around the world with the radio.net app

Get the free radio.net app
- Stations and podcasts to bookmark
- Stream via Wi-Fi or Bluetooth
- Supports Carplay & Android Auto
- Many other app features
Let's Combinate - Pharma + Medical Devices with Subhi Saadeh: Podcasts in Family














